title: Severe everolimus-induced steatohepatis: a case report.
abstract: The mammalian target of rapamycin inhibitors are normally favored as immunosuppressant agents for solid organ transplantation such as kidney, liver or heart. Only in recent years have they been increasingly administered for the treatment of neuroendocrine tumors. Even though mammalian target of rapamycin inhibitors are known to exhibit specific side effects, everolimus-related severe hepatic steatosis has not as yet been described in the literature. We report the case of a 76-year-old man who developed severe hepatic steatosis within four weeks of treatment with everolimus as concomitant tumor therapy for a progressively growing neuroendocrine carcinoma of the ileum. A diagnosis of hepatic steatosis was established using computer tomography and fibroscan©. Other underlying causes for steatosis hepatis could be excluded. Further studies are warranted to explain the underlying mechanisms.
authors.affiliation: Department of Radiation Oncology, Medical Faculty, Heinrich Heine University of Düsseldorf, Düsseldorf, Germany. boelke@med.uni-duesseldorf.de
authors.forename: Gisela
authors.initials: G
authors.lastname: Schieren
authors.forename: Edwin
authors.initials: E
authors.lastname: Bölke
authors.forename: Axel
authors.initials: A
authors.lastname: Scherer
authors.forename: Andreas
authors.initials: A
authors.lastname: Raffel
authors.forename: Peter Arne
authors.initials: PA
authors.lastname: Gerber
authors.forename: Patric
authors.initials: P
authors.lastname: Kröpil
authors.forename: Matthias
authors.initials: M
authors.lastname: Schott
authors.forename: Jackson
authors.initials: J
authors.lastname: Hamilton
authors.forename: Anne
authors.initials: A
authors.lastname: Hayman
authors.forename: Wolfram Trudo
authors.initials: WT
authors.lastname: Knoefel
authors.forename: Wilfried
authors.initials: W
authors.lastname: Budach
authors.forename: Christiane
authors.initials: C
authors.lastname: Matuschek
mesh_terms: D000368:Aged; D000068338:Everolimus; D005234:Fatty Liver / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008113:Liver Neoplasms / Q000175:diagnosis; D008297:Male; D018358:Neuroendocrine Tumors / Q000175:diagnosis; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus